Pankaj Bhangale
☆    

India,
2014-07-10 16:23
(3738 d 17:41 ago)

Posting: # 13255
Views: 7,024
 

 Multiple Outliers using Lund’s Procedure [Outliers]

Dear All,

We encountered a situation wherein the data shows only one outlier subject by Lund's procedure in 2X2 crossover design study. After removing this outlier subject, when the data is again run for Lund’s test, another outlier subject is observed.

Can we perform Lund’s test in such repetative manner to remove outliers from the data?

Is it acceptable by usfda regulatory subject to redosing study with multiple outlier subjects with control subjects)?


Please Guide me.
Really appreciate for any help.

Best Regards,
Pankaj Bhangale
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2014-07-10 17:42
(3738 d 16:22 ago)

@ Pankaj Bhangale
Posting: # 13256
Views: 6,012
 

 Repetitive testing?

Hi Pankaj,

❝ […] the data shows only one outlier subject by Lund's procedure in 2X2 crossover design study. After removing this outlier subject, when the data is again run for Lund’s test, another outlier subject is observed.


❝ Can we perform Lund’s test in such repetative manner to remove outliers from the data?


Please read the original publication.* IMHO, repetitive testing is statistically doubtful (politely speaking). We once faced a similar case 15+ years back when two outliers were detected and the French agency ‘discovered’ yet another one in the reduced data set. Agencies can do almost everything. I would not do it voluntarily. ;-)

Some remarks:
  • If you are BE with the complete data set, why bother? Nowadays most agencies are allergic against outlier testing and would even accept a study which shows BE with the outlier and fails without. Bizarre, but current practice.
  • Did you try to find a cause for the outlier (i.e., non-compliance, subject vomited, bioanalytical problems)?
  • Outliers inflate the variability and lead to failed studies more often than not. If you fail to show BE with the complete dataset and pass after removal of suspected outlier(s) you are in a gray-zone. It would help if you stated the planned procedure in the protocol. Otherwise it smells of cherry-picking. :cherry picking:
  • Since removal of outlier(s) decreases the CV, why do you want to decrease it even further by performing another ootlier test? Still not BE? Smells fishy to me. What does your protocol say?

❝ Is it acceptable by usfda regulatory subject to redosing study with multiple outlier subjects with control subjects)?


In principle, yes. However, the FDA has a strict policy against removal of outliers in non-replicated studies and accepts re-dosing only if the procedure was stated in the protocol. I would not recommend performing a re-dosing study without controled correspondence with CDER/OGD’s review staff (see this recent draft guidance; lines 644–647).


  • RE Lund
    Tables for An Approximate Test for Outliers in Linear Models
    Technometrics 17(4), 473–6 (1975)

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Pankaj Bhangale
☆    

India,
2014-07-11 15:30
(3737 d 18:34 ago)

@ Helmut
Posting: # 13259
Views: 5,752
 

 Repetitive testing?

Dear Helmut sir,

Thank you so much for the responce.

Best Regards,
Pankaj
UA Flag
Activity
 Admin contact
23,240 posts in 4,884 threads, 1,652 registered users;
63 visitors (0 registered, 63 guests [including 12 identified bots]).
Forum time: 10:04 CEST (Europe/Vienna)

[The] impatience with ambiguity can be criticized in the phrase:
absence of evidence is not evidence of absence.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5